Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Evidence-Based Hematology
This unique new book uses a series of focussed questions, comprehensive literature evaluations and structured grades of recommendation to provide evidence for the treatment of hematological disorders, both malignant and benign. With contributions from leading international experts who have a real understanding of evidence-based medicine the book provides comprehensive reviews accompanied by clinical commentaries and recommendations on the best treatment regimes to adopt for individual patients. The book is split into two sections: the first examines the methodology underlying evidence based practice, and the second concentrates on the clinical practice of hematology, providing current “best evidence” to guide practice in a series of well-defined clinical situations. This clinical reference is an invaluable source of evidence-based information distilled into guidance for clinical practice which will be welcomed by practitioners, trainees and associated health professionals.
Drug Resistance in Leukemia and Lymphoma III
Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts...
Chronic Myeloid Leukemia
Highly Commended, BMA Medical Book Awards 2014 Chronic myeloid leukemia is a clonal disease that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. Efforts to confront this disease have been assisted by advances in cellular and molecular biology and the speed at which these findings have transformed the therapeutic algorithm. Nevertheless, there is some uncertainty with regards to how best to assess efficacy of treatment, especially with regards to the most appropriate surrogate markers for overall survival. From the standpoint of biology and clinical management, this handbook provides an authoritative state-of-the-art review of current and developing progress.
Textbook of Malignant Hematology
The Second Edition of this successful title has been fully revised and updated and now includes expanded sections on normal and malignant haematopoiesis, offering a thorough review of the molecular and cellular processes involved in malignancy, developments in diagnostic techniques and treatment, concluding with discussion of treatment of individual diseases, late effects of therapy and supportive care. Short Contents
Textbook of Malignant Haematology
This textbook provides a concise overview of malignant haematology, including reviews of cell and molecular biology, and implications for new trends in treatment.
Pathogenesis and Treatment of Leukemia
This book covers a comprehensive update on acute and chronic leukemia. In 54 chapters, authors introduce research progress and clinical trials of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and chronic myeloid leukemia (CML). The last decade has seen the integration of genetic and clinical information to determine the prognosis and treatment strategies. This book provides practitioners, researchers and graduate students of Hematology and Hematopathology a comprehensive update on the pathobiology, genomics, classification, diagnosis, monitoring, prognostication and therapy of both acute and chronic leukemias.
Myeloproliferative Neoplasms
This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.
Platelets in Thrombotic and Non-Thrombotic Disorders
Platelets have become an important research target for clinicians and basic scientists in a range of medical disciplines. This book reviews current science and applications in fields including thrombosis and hemostasis, signal transduction, and non-thrombotic conditions such as inflammation, allergy and tumor metastasis. It is a detailed, up-to-date, highly referenced text for clinical scientists and physicians, including recent developments in this rapidly expanding field. It will be an essential reference for biomedical scientists and clinicians in hematology, vascular medicine, cardiology, thrombosis and related disciplines.
ThrombinIts Key Role in Thrombogenesis-Implications for Its Inhibition
This new multi-authored book reviews the current understanding of the role of thrombin in venous and arterial thrombosis and its inhibition in the clinical setting. Heparin, the most widely used antithrombotic, does not effectively regulate thrombin or its formation. Accumulating evidence suggests that other antithrombins are effective in some of the situations where heparin is not. Discussions include the current knowledge on antithrombotic prophylaxis and therapy, from the perspective of the role in thrombin in venous and arterial vascular disease, the limitations of the current anticoagulant therapies, and potential and limitations of newer antithrombins currently being tested in several experimental and clinical settings. Thrombin helps the clinician to better rationalize the use of specific antithrombins in the prevention and management of thrombotic disease and provides the basic scientist with a better understanding of the goals the clinician attempts to achieve with antithrombotic therapy.
Myeloproliferative Neoplasms: Biology and Treatment
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) - including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PM) - are clonal stem cell disorders characterized by acquired activating mutations which result in an excessive production of red blood cells, platelets, and neutrophils. Recent advances in the understanding of the molecular biology and genomics of MPNs have led to the development of novel targeted treatment approaches; however, the high rate of life-threatening vascular events and the high risk of disease progression with myelofibrotic and leukemic transformation continue to present challenges in the management of MPNs. Thereby, there remains a need for novel treatment strategies. Recently, research has revealed a role for clonal hematopoiesis, driver mutations and inflammation in thrombosis risk, which may provide a basis for novel thrombosis-prevention strategies.
